期刊文献+

蛋白质多肽药物聚乙二醇定点修饰的研究进展 被引量:5

The research progress of protein and peptide site-PEGylation
原文传递
导出
摘要 聚乙二醇修饰可以很好地解决蛋白多肽药物难溶性、稳定性差、半衰期短、毒性大、免疫原性等问题,其中的聚乙二醇定点修饰方式更具优势。本文着重介绍聚乙二醇在蛋白多肽药物中的N端氨基、巯基、羧基和糖类残基及N端氧化后的定点修饰方式的研究进展。 PEGylation of proteins and peptides could resolve many problems such as increasing solubility, enhancing stability, prolonging half-lives, reducing toxicity and shielding immunogenic epitopes. The progress of site-PEGylation for amino, thiol, carboxyl and oxidized aldehyde groups are reviewed.
出处 《军事医学科学院院刊》 CSCD 北大核心 2007年第2期178-182,共5页 Bulletin of the Academy of Military Medical Sciences
关键词 蛋白质 多肽 聚乙二醇定点修饰 protein peptide site-PEGylation
  • 相关文献

参考文献25

  • 1Veronese FM,Pasut G.PEGylation,successful approach to drug delivery[J].Drug Diseov Today,2005,10(21):1451-1458.
  • 2Roberts MJ,Bentley MD,Harris JM.Chemistry for peptide and protein PEGylation[J].Adv Drug Deliv Rev,2002,54(4):459-476.
  • 3Nancy E,Christine E.N-terminally chemically modified protein compositions and methods[P].US Patent,7090835,2006-08-15.
  • 4Lee S,Wylie DC,Susan V,et al.Pegylated interleukin-10[P].US Patent,7052686,2006-5-30.
  • 5El-Tayar,Roberts MJ,Harris M,et al.Polyol-IFN-β conjugates modified at cys-17 and composition containing same[P].US Patent,6638500,2003-10-28.
  • 6Basu A,Yang K,Wang M,et al.Structure-function engineering of interferon-beta-1b for improving stability,solubility,potency,immunogenicity,and pharmacokinedc properties by site-selective mono-PEGylation[J].Bioconjug Chem,2006,17(3):618-630.
  • 7Na DH,Lee KC,Dluca PP.PEGylation of octreotide Ⅱ.Effect of N-terminal mono-PEGylation on biological activity and pharmaeokinefics[J].Pharm Res,2005,22(5):743-749.
  • 8Lee H,Park TG.Preparation and characterization of mono-PEGylated epidermal growth factor:evaluation of in vitro biologic activity[J].Pharm Res,2002,19(6):845-851.
  • 9Lee H,Jang H,Ryu SH,et al.N-terminal site-specific monoPEGylation of epidermal growth factor[J].Pharm Res,2003,20(5):818-825.
  • 10Yamamoto Y,Tsutsumi Y,Yoshioka Y,et al.Site-specific PEGylation of a lysine-deficient TNF-alpha with full bioactivity[J].Nat Biotechnol,2003,21(5):546-552.

二级参考文献2

  • 1唐微,Tetrahedron Lett,1994年,35卷,35期,6515页
  • 2王子轩,中国科学.B,1994年,24卷,10期,1066页

共引文献4

同被引文献48

  • 1徐静,倪道明,张振龙.聚乙二醇修饰β-干扰素的研究[J].微生物学免疫学进展,2004,32(3):30-33. 被引量:3
  • 2Dhalluin C, Ross A, Leuthold LA, et al. Structural and biophysical characterization of the 40 kDa PEG-Interferon-α2a and Its Individ- ual Positional Isomers. Bioconjugate Chem, 2005, 3( 16): 504-517.
  • 3Ceaglio N, Etcheverrigaray M, Kratje R, et al. Novel long-lasting interferon alpha derivatives designed by glycoengineering. Biochimie, 2008, 90(3): 437-449.
  • 4Glue P, Fang JW, Rouzier-Pains R, et al. Pegylated interferon α2b: pharmacokinetics, pharmacody-namics,safety and preliminary efficacy data. Clin Pharmacol Ther, 2000, 68(5 ): 556-567.
  • 5Fee C J, Van Alstine JM. PEG-proteins: reaction engineering and separation issues. Chem Engineering Sci, 2006, 61 (3): 924-939.
  • 6Wu X, Li X, Zeng Y, et al. Site-directed PEGylation of human basic fibroblast growth factor. Protein Expr Purif, 2006, 48 (1): 24-27.
  • 7沈纯,纪英,陈晓春,等.PEG化干扰素α-1b.中国,200510076676.X.2006-04-05.
  • 8刘耀波,杨轶,刘金毅等.新型α干扰素突变体及其制备方法.中国专利,CNl511849.2004-07-14
  • 9Tischio J P,Patrick J E,Weintraub H S,et al.Short in vitro half-life of thymopoietin 32-36 pentapeptide in human plasma[J].Int JPharm,1979,14:479-484.
  • 10Paolo C,Francesco M V.Pharmacokinetic and biodistribution prop-erties of poly(ethylene glycol)-protein conjugates[J].Adv DrugDeliver Rev,2003,55:1261-1277.

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部